CellPro Inc. has begun marketing its first product, the CeprateLC (CD34) Laboratory Cell Separation System, for cellularresearch.

The monoclonal antibody-based system can be used to purifystem cells from bone marrow or blood. Stem cells, whichconstitute less than 1 percent of all cells in bone marrow, areresponsible for generating all blood cells.

CellPro estimates the world market for research cellseparations at $50 million to $75 million. The Bothell, Wash.,company said the market is growing more than 10 percentannually.

CellPro stock (NASDAQ:CPRO) closed unchanged at $15.50 onThursday. The company sold 3 million shares at $11 in aninitial public offering in September.

(c) 1997 American Health Consultants. All rights reserved.